Spots Global Cancer Trial Database for Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

Official Title: Trabectedin and Irinotecan in Pediatric Refractory Sarcomas

Study ID: NCT02509234

Conditions

Recurrent Childhood Soft Tissue Sarcoma

Recurrent Ewing Sarcoma

Recurrent Rhabdomyosarcoma

Interventions

Combined chemotherapy with trabectedin followed by irinotecan

Study Description

Brief Summary: The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.

Detailed Description:

Keywords

Eligibility

Minimum Age: 10 Years

Eligible Ages: CHILD, ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Name: Stefan Burdach, Prof.

Affiliation: Kinderklinik München Schwabing - Klinik und Poliklinik für Kinder- und Jugendmedizin, Klinikum Schwabing, Städtisches Klinikum München GmbH und Klinikum Rechts der Isar (AöR) der Technischen Universität München

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: